## Novel and Emerging Therapies in Severe Asthma

Elliot Israel, M.D. Gloria and Anthony Simboli Professor of Medicine Harvard Medical School Pulmonary & Critical Care Medicine Allergy & Immunology Partners' Asthma Center BWH Severe Asthma Progam



#### I disclose the following relationships in the past year:

- Asthma Education Prevention Program (NAEPP) Coordinating • 2017-Committee
- **AB** Science
- Amgen
- AstraZeneca
- Avillion
- **Circassia Pharmaceuticals**
- Cowen
- GlaxoSmithKline
- **Gossamer Bio**
- Merck
- Novartis



- Pneuma Respiratory **PPS Health Regeneron Pharmaceuticals** Sanofi
- TEVA


Consultant Consultant **Consultant & Clinical Research** Support **Consultant & Clinical Research** Support **Clinical Research Support** Consultant Consultant **Clinical Research Support** Consultant Consultant Consultant Consultant Consultant ASTHMA CENTE Consultant **Consultant & Clinical Research** 

#### Novel Approaches in Development that Are Being Tested in Humans

- Anti CRTH2
- Mast cell inhibitors
- GATA3 Inhibitors
- Anti-IL33
- Other approaches










# FEV1 Improvement to CRTh2 Antagonist (OC)Greater in those with Higher Eosinophils

Eos <u>></u>250/ul


Eos <250/ul








## Fevipiprant Increased FEV1 in Allergic Patients on Low Dose ICS






#### Fevipiprant Increased Intact Epithelium and Decreased Denuded Epithelium



ASTHM

#### Fevipiprant Improved ACQ5 and Post-BD-FEV1 in Patients on ICS w/ Sputum Eos








## **CRTh2 Antagonists**

- Was being studied in moderate to severe patients
- Oral tablets
- Novartis announced that fevipiprant failed to improve FEV1 in 2 phase 3 trials
- Novartis announced that the 1 year exacerbation trials failed to meet their endpoint
- GB001 an oral DP<sub>2</sub> antagonist
  - Failed in asthma but perhaps a 1/3 reduction in exacerbations



- Failed in chronic rhinosinusitis








#### **DNAzyme Against GATA3 mRNA decreases the FEV1 Response to Allergen Challenge**

(Post-challenge sputum eosinophils and tryptase and serum IL5 decreased, but not FeNO or Mch PC<sub>20</sub>)




ERF



- Phase 2b Studies in Asthma are being prepared
- Phase 2a study in COPD with elevated sputum eosinophils showed reduction in sputum eosinophils with inhaled DNAzyme











# Imatinib Improved Airway Hyperresponsiveness in Patients with Severe Asthma




Cahill et al. NEJM, 2017


# Imatinib Improved FEV<sub>1</sub> and Correlated with Decline in Airway Mast Cells



Cahill et al. NEJM, 2017

## Imatinib was Most Effective in those with Reduced Evidence of T2 Inflammation





Cahill et al. NEJM, 2017

## Imatinib

#### Being studied in NIH Precision Medicine in Severe Asthma (PrecISE) network






## **Masitinib**

- Second generation tyrosine kinase inhibitor
- Company released results showing a decrease in exacerbations in patients with severe asthma on oral corticosteroids












#### Anti-IL33 Reduced Time to Loss of Asthma Control to the Same Extent as Dupilumab & Was Not Additive



### **Anti-IL33 Reduced Eosinophils**



### Anti-IL33 Appears to Have a Possible Effect on FeNO and IgE






#### The greatest improvement was seen in patients with eosinophils <u>></u>300/ul











#### Anti-IL17RA

#### NO ACQ Response in Overall Population (Acq>1.5 on >200 ICS w/ >12% BDR and no required exacerbations) <2

Inconsistent Dose Trend in ACQ Response to Anti 17RA in Patient > with >20% BDR










## Annual Rate of Asthma Worsening was Increased by Anti-IL23







Brightling CE et al. N Engl J Med 2021;385:1669-1679



# ACQ5, FEV<sub>1</sub>, PEF, and Rescue Use were worse or no better with Anti-IL23







## Additional Phase 1 and Phase 2 Agents and Targets

- Azithromycin
- Targeting MUC5AC
- Targeting the JAK Kinases
- Targeting MMP 12 macrophage elastase
- Administration of bacteria that downregulate T2 responses
- CGRP antagonists
- Anti-IL6
- Targeting )X40 Ligand expressed on memory T2 cells
- 8 expressed on eosinophils and mast cells





Х

## Additional Phase 1 and Phase 2 Agents and Targets

- FLAP antagonists
- GLP1 receptor antagonistgs in obesity-related asthma
- LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). –
- Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
- Targeting βc, CD131- receptor β common for -signaling cytokines interleukin (IL)-3, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-5 (
- CXA10 an endogenous nitro-fatty acid (NFA) modulator of Nrf2 and NF-κB in obesity associated asthma



SM17 - monoclonal antibodies targeting IL17BR blocking IL17B and E -Anti-Siglec

ASTHMA CENTE

### **Summary**

- Additional therapies targeting Type 2 pathway are being developed
- The greatest unmet need persists in non-Type 2 disease





Х